Rznomics Inc based biopharmaceutical company specializing in RNA-based therapeutics, announced today that it has entered into a strategic global research collaboration and licensing agreement with Eli Lilly and Company to develop and commercialize novel RNA-editing therapies using Rznomics' proprietary trans-splicing ribozyme platform..

Rznomics Inc基于生物制药公司，专注于RNA治疗领域，今日宣布与礼来公司达成战略性的全球研究合作与许可协议，利用Rznomics专有的反式剪接核酶平台开发和商业化新型RNA编辑疗法。

The collaboration focuses on the discovery and development of RNA-editing therapeutics for sensorineural hearing loss. Rznomics will conduct early-stage research according to the jointly approved research plans, while Lilly will assume responsibility for further development and commercialization.

该合作专注于发现和开发针对感音神经性听力损失的RNA编辑疗法。Rznomics将根据共同批准的研究计划进行早期研究，而礼来公司将负责进一步的开发和商业化。

If Lilly exercises all available options under the agreement, the total deal value could reach more than

如果 Lilly 行使协议下的所有可用选项，总交易价值可能达到更多

$1.3 billion

13亿美元

, as well as separate royalties on product sales. In line with the mutual understanding between the two companies, the upfront payment was not disclosed.

，以及产品销售的单独专利税。根据两家公司之间的相互理解，预付款未被披露。

'We are thrilled to collaborate with Lilly, a global leader in pharmaceutical innovation,' said Dr. Seong-Wook Lee, CEO of Rznomics. 'This partnership validates our trans-splicing ribozyme platform and opens the door to treating previously intractable diseases with precision RNA therapeutics. Together with Lilly, we aim to accelerate the development of transformative therapies for patients around the world.'.

“我们非常高兴能与全球制药创新领域的领导者礼来公司合作，”Rznomics首席执行官李盛旭博士表示，“此次合作验证了我们的反式剪接核酶平台，并为利用精准RNA治疗以前难以攻克的疾病打开了大门。与礼来携手，我们旨在加速为全球患者开发变革性疗法。”

This partnership marks a significant milestone for Rznomics as it seeks to expand its presence in the global biotech arena. For Lilly, the deal aligns with its broader strategy to build a leading RNA therapeutics pipeline and address high unmet needs in hearing loss and other therapeutic areas.

这一合作标志着Rznomics在寻求扩大其在全球生物技术领域的影响力方面迈出了重要的一步。对于礼来公司而言，该协议与其建立领先的RNA治疗产品线并满足听力损失及其他治疗领域高度未满足需求的广泛战略相契合。

About Rznomics

关于Rznomics

Rznomics is a clinical-stage biopharmaceutical company based in

Rznomics是一家临床阶段的生物制药公司，总部位于

South Korea

韩国

focused on developing RNA-based gene therapies. The company's proprietary trans-splicing ribozyme platform enables precise RNA editing and has broad applicability across multiple indications.

专注于开发基于RNA的基因疗法。该公司专有的反式剪接核酶平台能够实现精确的RNA编辑，并在多种适应症中具有广泛的应用性。